Fairpointe Capital’s Standard BioTools LAB Stock Holding History

Fairpointe Capital’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-65,000	Closed	-$301K	–	79
2019 Q3	$301K	Hold	65,000	–	–	0.02%	72
2019 Q2	$801K	Hold	65,000	–	–	0.03%	58
2019 Q1	$864K	Hold	65,000	–	–	0.03%	59
2018 Q4	$560K	Buy	65,000 +25,000	+63%	+$195K	0.02%	64
2018 Q3	$300K	Hold	40,000	–	–	0.01%	73
2018 Q2	$238K	Buy	+40,000	New	+$228K	0.01%	78

Other funds holding LAB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Fairpointe Capital's LAB Position: Q4 2019 in Review

Fairpointe Capital sold out of Standard BioTools (LAB) in Q4 2019, closing a stake of 65,000 shares — an estimated $301K sold.

Fairpointe Capital first reported a position in LAB in Q2 2018 and held it in 6 quarters. The position peaked at $864K in Q1 2019. 99 funds tracked by Wall St. Rank hold LAB as of Q4 2019.

Fairpointe Capital reported no remaining Standard BioTools position as of Q4 2019 after selling out during the quarter.
Fairpointe Capital sold 65,000 Standard BioTools shares in Q4 2019, an estimated $301K.
Fairpointe Capital first reported a position in Standard BioTools in Q2 2018 and held it in 6 quarters.
Fairpointe Capital's Standard BioTools position peaked at $864K in Q1 2019.
99 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2019.

Based on Fairpointe Capital's 13F filing for Q4 2019, filed 14 Feb 2020.